Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2007;2(2):93-4.

Which bronchodilator in COPD?

Richard Russell, Dave Singh
Editorial

Which bronchodilator in COPD?

Richard Russell et al. Int J Chron Obstruct Pulmon Dis. 2007.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Aaron SD, Vandemheen KL, Fergusson D, et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545–55. - PubMed
    1. Celli BR, Roger S. Mitchell lecture. Chronic obstructive pulmonary disease phenotypes and their clinical relevance. Proc Am Thoracic Soc. 2006;3:461–5. - PubMed
    1. Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD. 2004;1:303–12. - PubMed
    1. Hodder R, Kesten S, Menjoge S, et al. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int J COPD. 2007;2:157–167. - PMC - PubMed
    1. Rice KL, Kunisaki KM, Niewoehner DE. Role of tiotropium in the treatment of chronic obstructive pulmonary disease. Int J COPD. 2007;2:95–105. - PMC - PubMed

MeSH terms